253 related articles for article (PubMed ID: 20543007)
1. Structure-based engineering of a monoclonal antibody for improved solubility.
Wu SJ; Luo J; O'Neil KT; Kang J; Lacy ER; Canziani G; Baker A; Huang M; Tang QM; Raju TS; Jacobs SA; Teplyakov A; Gilliland GL; Feng Y
Protein Eng Des Sel; 2010 Aug; 23(8):643-51. PubMed ID: 20543007
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
[TBL] [Abstract][Full Text] [Related]
3. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
4. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
5. Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607.
Teplyakov A; Obmolova G; Wu SJ; Luo J; Kang J; O'Neil K; Gilliland GL
J Mol Biol; 2009 May; 389(1):115-23. PubMed ID: 19361524
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling of cardiac glycoside binding by the human sequence monoclonal antibody 1B3.
Paula S; Monson N; Ball WJ
Proteins; 2005 Aug; 60(3):382-91. PubMed ID: 15971203
[TBL] [Abstract][Full Text] [Related]
7. Human framework adaptation of a mouse anti-human IL-13 antibody.
Fransson J; Teplyakov A; Raghunathan G; Chi E; Cordier W; Dinh T; Feng Y; Giles-Komar J; Gilliland G; Lollo B; Malia TJ; Nishioka W; Obmolova G; Zhao S; Zhao Y; Swanson RV; Almagro JC
J Mol Biol; 2010 Apr; 398(2):214-31. PubMed ID: 20226193
[TBL] [Abstract][Full Text] [Related]
8. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
[TBL] [Abstract][Full Text] [Related]
9. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
10. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.
Xiang J; Sha Y; Jia Z; Prasad L; Delbaere LT
J Mol Biol; 1995 Oct; 253(3):385-90. PubMed ID: 7473721
[TBL] [Abstract][Full Text] [Related]
11. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody.
Midelfort KS; Hernandez HH; Lippow SM; Tidor B; Drennan CL; Wittrup KD
J Mol Biol; 2004 Oct; 343(3):685-701. PubMed ID: 15465055
[TBL] [Abstract][Full Text] [Related]
12. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
13. Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments.
Leung S; Losman MJ; Govindan SV; Griffiths GL; Goldenberg DM; Hansen HJ
J Immunol; 1995 Jun; 154(11):5919-26. PubMed ID: 7751635
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of self-association of a human monoclonal antibody CNTO607.
Bethea D; Wu SJ; Luo J; Hyun L; Lacy ER; Teplyakov A; Jacobs SA; O'Neil KT; Gilliland GL; Feng Y
Protein Eng Des Sel; 2012 Oct; 25(10):531-7. PubMed ID: 22915597
[TBL] [Abstract][Full Text] [Related]
15. Design and application of antibody cysteine variants.
Voynov V; Chennamsetty N; Kayser V; Wallny HJ; Helk B; Trout BL
Bioconjug Chem; 2010 Feb; 21(2):385-92. PubMed ID: 20092294
[TBL] [Abstract][Full Text] [Related]
16. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.
Perchiacca JM; Ladiwala AR; Bhattacharya M; Tessier PM
Protein Eng Des Sel; 2012 Oct; 25(10):591-601. PubMed ID: 22843678
[TBL] [Abstract][Full Text] [Related]
17. Structure of IL-17A in complex with a potent, fully human neutralizing antibody.
Gerhardt S; Abbott WM; Hargreaves D; Pauptit RA; Davies RA; Needham MR; Langham C; Barker W; Aziz A; Snow MJ; Dawson S; Welsh F; Wilkinson T; Vaugan T; Beste G; Bishop S; Popovic B; Rees G; Sleeman M; Tuske SJ; Coales SJ; Hamuro Y; Russell C
J Mol Biol; 2009 Dec; 394(5):905-21. PubMed ID: 19835883
[TBL] [Abstract][Full Text] [Related]
18. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
Pantophlet R; Wilson IA; Burton DR
Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
[TBL] [Abstract][Full Text] [Related]
19. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M
Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729
[TBL] [Abstract][Full Text] [Related]
20. Antibody affinity maturation in vitro using unconjugated peptide antigen.
Iwai H; Oztürk B; Ihara M; Ueda H
Protein Eng Des Sel; 2010 Apr; 23(4):185-93. PubMed ID: 20123883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
